---
title: "CSPC PHARMA: GLP-1 / GIP receptor dual agonist peptide injection (SYH2069 injection) has been approved for clinical trials in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270981595.md"
description: "CSPC PHARMA announced that its developed GLP-1/GIP receptor dual-bias agonist peptide injection (SYH2069) has been approved by the National Medical Products Administration of China for clinical trials. The product has also been approved by the FDA to conduct clinical trials in the United States and is expected to become the first of its kind to enter the clinical stage in China, with significant weight loss and metabolic improvement effects, suitable for weight management in obesity and related complications, and has the potential to improve blood sugar control in patients with type 2 diabetes"
datetime: "2025-12-29T10:26:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270981595.md)
  - [en](https://longbridge.com/en/news/270981595.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270981595.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/270981595.md) | [繁體中文](https://longbridge.com/zh-HK/news/270981595.md)


# CSPC PHARMA: GLP-1 / GIP receptor dual agonist peptide injection (SYH2069 injection) has been approved for clinical trials in China

According to the announcement from CSPC PHARMA (01093), the GLP-1/GIP receptor dual agonist peptide injection (SYH2069 injection) developed by the group has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. Previously, this product also received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States.

This product is expected to become the first GLP-1/GIP receptor dual agonist to enter the clinical stage in China, selectively activating the cAMP pathway, significantly reducing β-arrestin recruitment, thereby decreasing receptor internalization and desensitization, and enhancing drug efficacy and duration of effect. Additionally, combined with a long half-life modification platform technology, this product can achieve deeper and more sustained weight loss effects. In studies on diet-induced obesity (DIO) mice and non-human primates, this product demonstrated significantly better effects on weight loss and metabolic improvement compared to similar products on the market. Repeated-dose toxicology studies in non-human primates showed good tolerance for this product, with no observed vomiting or gastrointestinal adverse reactions. This product exhibits excellent efficacy and good safety, and is expected to become a new generation therapy for overweight/obesity and other metabolic diseases.

The approved clinical indication for this product is weight management in populations with obesity or overweight and at least one weight-related comorbidity. Furthermore, this product also has the potential to improve blood glucose control in adults with type 2 diabetes (T2DM), possessing high clinical development value

### Related Stocks

- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/en/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/en/news/280502605.md)
- [Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials](https://longbridge.com/en/news/280731966.md)
- [Yunnan Baiyao Gets Nod to Trial INB301 Injection](https://longbridge.com/en/news/281464510.md)
- [KKR, GIP Among Bidders for French Fiber Network](https://longbridge.com/en/news/280507386.md)